THE EFFICACY AND COST-EFFECTIVENESS OF HYDROXYCHLOROQUINE, SULFASALAZINE, METHOTREXATE TRIPLE THERAPY IN PREVENTING RELAPSE OF RHEUMATOID ARTHRITIS

被引：1
|
作者：
Zhao, J. [1 ]
Zhou, W. [1 ]
Wu, Y. [2 ]
Ji, P. [2 ]
Yan, X. [2 ]
Yang, L. [3 ]
Zhang, Z. [1 ]
机构：
[1] Peking Univ, Rheumatol & Immunol Dept, Hosp 1, Beijing, Peoples R China
[2] Peking Univ Clin Res Inst PUCRI, Beijing, Peoples R China
[3] Peking Univ, Sch Publ Hlth, Beijing, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.1926
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0143
引用
收藏
页码：651 / 651
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of anakinra plus methotrexate versus methotrexate alone for the treatment of rheumatoid arthritis.
    Guh, DP
    Marra, CA
    Woolcott, JC
    Gignac, M
    Esdaile, JM
    Clarke, A
    Anis, AH
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S264 - S264
  • [32] COMBINATION THERAPY WITH METHOTREXATE AND SULFASALAZINE IN RHEUMATOID-ARTHRITIS - TOLERANCE OF THERAPY
    AXTENS, RSK
    MORAND, EF
    LITTLEJOHN, GO
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1994, 53 (10) : 703 - 703
  • [33] Methotrexate (M) sulfasalazine (S) hydroxychloroquine (H) combination therapy in rheumatoid arthritis (RA): Continued efficacy with minimal toxicity at 3 years.
    ODell, J
    Haire, C
    Drymalski, W
    Palmer, W
    Eckhoff, PJ
    Maloley, P
    Klassen, L
    Wees, S
    Klein, H
    Moore, G
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 578 - 578
  • [34] COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS TOCILIZUMAB PLUS METHOTREXATE IN RHEUMATOID ARTHRITIS TREATMENT
    Oksuz, E.
    Malhan, S.
    Yanik, L.
    Koc, E.
    Erdogan-Ciftci, E.
    Celik, H.
    Orfanos, P.
    [J]. VALUE IN HEALTH, 2018, 21 : S295 - S295
  • [35] COST-EFFECTIVENESS OF BIOLOGIC AGENTS COMPARED WITH METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN COLOMBIA
    Valle-Mercado, C.
    Cubides, M. F.
    Parra-Torrado, M.
    Rosselli, D.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A311 - A311
  • [36] COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS TOCILIZUMAB WITHOUT METHOTREXATE IN RHEUMATOID ARTHRITIS TREATMENT
    Oksuz, E.
    Malhan, S.
    Yanik, L.
    Koc, E.
    Erdogan-Ciftci, E.
    Celik, H.
    Orfanos, P.
    [J]. VALUE IN HEALTH, 2018, 21 : S297 - S297
  • [37] Cost-effectiveness of treatment strategies for rheumatoid arthritis patients with inadequate response to methotrexate
    Patel, VD
    Hay, J
    [J]. VALUE IN HEALTH, 2004, 7 (03) : 241 - 241
  • [38] Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial
    de Jong, P. H. P.
    Weel, A. E. A. M.
    Luime, J. J.
    Barendregt, P. J.
    Gerards, A. H.
    van der Lubbe, P. A.
    de Jager, M. H.
    de Sonnaville, P. B.
    van Zeben, D.
    Grillet, B. A.
    Hazes, J. M. W.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S753 - S754
  • [39] Retention of Triple Therapy With Methotrexate, Sulfasalazine, and Hydroxychloroquine Compared to Combination Methotrexate and Leflunomide in Rheumatoid Arthritis, a Real-World Data From the Ontario Best Practices Research Initiative
    Bhavsar, Sankalp
    Movahedi, Mohammad
    Cesta, Angela
    Pope, Janet
    Bombardier, Claire
    [J]. JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 35 - 36
  • [40] Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis
    Salaffi, F
    Carotti, M
    Cervini, C
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1996, 25 (01) : 16 - 23
12345